Skip to main content

Table 1 Baseline characteristics of training and validation cohorts

From: Development and validation of a nomogram model based on pretreatment ultrasound and contrast-enhanced ultrasound to predict the efficacy of neoadjuvant chemotherapy in patients with borderline resectable or locally advanced pancreatic cancer

 

Training cohort

Validation cohort

P value

Age(year)

59.41 ± 1.52

60.44 ± 0.99

0.93

Sex (Male/Female)

29/27

31/24

0.63

CA19-9(U/mL)

437.32 ± 122.90

879.13 ± 184.70

0.05

Tumor size(cm, IQR)

4.98(1.95)

4.27(1.75)

0.27

Location

  

0.22

 Head or neck

29

17

 

 Body or tail

48

17

 

Tumor Stage (BRPC/LAPC)

18/59

9/25

0.73

Treatment (AG/AS)

41/36

18/16

0.98

  1. IQR Interquartile range, BRPC Borderline resectable pancreatic cancer, LAPC Locally advanced pancreatic cancer, AG Nab-paclitaxel + gemcitabine, AS Nab-paclitaxel + tegafur
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us